β-Ethylpentamethylensulfid | 61568-48-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 英文名称: β-Ethylpentamethylensulfid
• 英文别名: 3-Aethyl-pentamethylensulfid；3-Ethyl-thiacyclohexan；3-Ethyl-pentamethylensulfid；3-Aethyl-tetrahydro-thiopyran；3-ethyl-tetrahydro-thiopyran；3-Ethylthiane
• CAS: 61568-48-7
• 化学式: C₇H₁₄S
• 分子量: 130.254
• InChiKey: CIMHGPVZHGEPEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] SLC2A TRANSPORTER INHIBITORS<br/>[FR] INHIBITEURS DU TRANSPORTEUR SLC2A
  申请人：IOMET PHARMA LTD

  公开号：WO2014187922A1

  公开（公告）日：2014-11-27

  Provided is a SLC2A class I transporter inhibitor compound for use in medicine, which compound comprises the following formula (I): wherein A and Z may be the same or different and are each independently selected from C, N, O and S; each X may be the same or different and is independently selected from C, N, O and S; R1 and R5 may be present or absent and may be the same or different and are each selected from H and a substituted or unsubstituted organic group; Z completes a ring with each X, each ring comprising from 3 to 8 ring atoms including the X, A, and Z, each ring atom being independently selected from C, N, O and S, and each ring atom being unsubstituted or independently substituted with H or a substituted or unsubstituted organic group; and wherein the bonds between all of the atoms in the rings including the X, A, and Z may independently be single bonds or double bonds, provided that when X or a ring atom is O or S the bonds to X are single bonds.

  提供了一种用于药物的SLC2A类I转运体抑制剂化合物，该化合物包括以下结构式（I）：其中A和Z可以相同也可以不同，分别独立地选自C、N、O和S；每个X可以相同也可以不同，独立地选自C、N、O和S；R1和R5可以存在也可以不存在，可以相同也可以不同，分别选自H和一个取代或未取代的有机基团；Z与每个X形成一个环，每个环包括从3到8个环原子，包括X、A和Z，每个环原子独立地选自C、N、O和S，并且每个环原子未取代或独立地取代为H或一个取代或未取代的有机基团；所有环中的原子之间的键包括X、A和Z可能独立地为单键或双键，但当X或环原子为O或S时，与X的键为单键。
• Compounds useful for treating neurodegenerative disorders
  申请人：Bronk Brian Scott

  公开号：US20130060020A1

  公开（公告）日：2013-03-07

  The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R x is as defined and described herein, compositions thereof, and methods of using the same.

  本发明提供了公式I的化合物：或其药学上可接受的盐，其中Rxis的定义和描述如本文所述，以及其组合物和使用方法。
• BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETALACTAMASE INHIBITORS
  申请人：NAEJA PHARMACEUTICAL INC.

  公开号：US20140221341A1

  公开（公告）日：2014-08-07

  A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR 1 or NR 2 R 3 , and R 1 , R 2 , R 3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

  化合物的式子(I)：其中：M是氢或药用可接受的盐形成阳离子；Y是OR1或NR2R3，而R1、R2、R3和M的定义如本文所述。此外，还提供了治疗细菌感染的方法、制药组合物、分子复合物和制备化合物的过程。
• Pharmaceutical Compound
  申请人：IOMET PHARMA LTD

  公开号：US20160367564A1

  公开（公告）日：2016-12-22

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X 2 , X 4 , X 10 , and X 11 may be the same or different and each is independently selected from C and N; X 1 , X 3 , X 5 , X 6 , X 7 , X 8 , and X 9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X 4 with the carbon atoms either side of X 2 are single bonds, and are only present when X 2 is absent, X 3 is absent and X 4 is C, and when these bonds are present the ring carbons on each side of X 2 are not directly bonded to each other; each R 1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 1 groups present is such that the valency of X 1 is maintained; each R 12 , R 13 , R 13′ , R 14 , R 15 and R 15′ may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R 16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 16 groups present is such that the valency of X 2 is maintained; each R 17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R 17 groups present is such that the valency of X 3 is maintained; each R 2 , R 3 , R 4 , and R 5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 6 , X 7 , X 8 , and X 9 are maintained; each R 7 , R 8 and R 9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 10 , X 11 , and X 5 are maintained; and R 6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C 1 -C 6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.
• US9393239B2
  申请人：——

  公开号：US9393239B2

  公开（公告）日：2016-07-19

表征谱图